Its roles Owner Operator Offtaker
Bayer AG is a German multinational life science and chemical company headquartered in Leverkusen, founded in 1863. Its core businesses span Pharmaceuticals, Consumer Health, and Crop Science, with activities ranging from discovery and development to large‑scale manufacturing of active pharmaceutical ingredients (such as acetylsalicylic acid), over‑the‑counter health products, seeds, and crop protection chemicals. The company operates a global network of research, production, and distribution sites, including regional entities such as Bayer Taiwan Co., Ltd.
For the chemical industry, Bayer is notable for its pharmaceutical and agrochemical process chemistry and legacy in materials science; its materials business was separated as Covestro in 2015. Bayer is pursuing energy transition measures in its operations, including long‑term power and heat purchase agreements to support electrification and decarbonization at manufacturing sites, such as the acetylsalicylic acid plant in La Felguera, Spain.
Also known as Bayer Group, Bayer AG Taiwan Branch, Bayer Taiwan Co., Ltd., and Bayer Taiwan.
chemXplore tracks 20 projects involving Bayer, of which 3 are active.
Besides these 3, the record holds 16 completed projects and 1 cancelled.
Closest to start-up first.
The 17 that are completed, on hold or cancelled are in the record. See all 20 in chemXplore →
FDA acceptance of finerenone sNDA for adults with CKD without diabetes follows Phase III FIND‑CKD showing slower eGFR decline and reduced cardio‑kidney events versus placebo.
2.2 billion USD project in New Albany will add ~600 permanent roles and ~1,500 construction jobs; first drug substance module operational in 2031, drug product in 2034.
Ten projects won awards across six categories for initiatives linking electrification, biodiversity and rural development, from industrial decarbonisation to community energy and journalism.
Investigational iPSC-derived cell therapy for primary photoreceptor diseases receives orphan status across multiple inherited retinal disorder indications; being tested in a Phase 1/2a trial.
FDA accepted the sNDA and granted Priority Review for Lynkuet to treat moderate to severe vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
Funding will accelerate US launch of one‑time engineered microbes that claim season‑long control of fungal diseases; ARGO™ platform promises sub‑20‑month development.
FDA clears finerenone to reduce UACR in adults with CKD linked to type 1 diabetes, aiming to slow eGFR decline and lower risk of end‑stage kidney disease.
Uta Kemmerich-Keil (59), former head of P&G International Personal Healthcare, joins the Supervisory Board, succeeding Dr. Heike Hanagarth, who did not stand for re-election.
active all projects
What each is building and closing, and the pipelines and grids between them, on one map.
